Immunic's vidofludimus calcium shows sustained disability benefits in Phase 2 MS trial extension
IMUX•Immunic said continued treatment in the Phase 2 CALLIPER extension showed sustained favorable disability trends, with safety consistent with the double-blind period. Exploratory analyses linked reduced Epstein-Barr virus-specific immune signatures to improved cognitive performance.
1. Extension study findings
Immunic presented Phase 2 CALLIPER extension findings showing sustained favorable disability trends with continued vidofludimus calcium treatment; safety remained consistent with the double-blind period. Exploratory analyses linked reduced Epstein-Barr virus-specific immune signatures to improved cognitive performance, while preclinical findings suggested neuroprotective effects involving Nurr1 activation. Immunic plans a Phase 3 progressive MS program for later this year and expects relapsing MS trial results by year-end 2026.
